Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the antibody into patient studies for IgA nephropathy.